medigraphic.com
ISSN 1995-9427 (Impreso)

2023, Número 1

<< Anterior Siguiente >>

Invest Medicoquir 2023; 15 (1)


Tratamiento con toxina botulínica en pacientes con diagnóstico de espasmo hemifacial

Rodríguez LA, Maragoto RC, Maragoto PE, Gonzales GI, Gil NL

Idioma: Español
Referencias bibliográficas: 51
Paginas:
Archivo PDF: 217.16 Kb.


RESUMEN

Introducción. El espasmo hemifacial se caracteriza por las contracciones involuntarias y repetidas de los músculos de una hemicara. La inyección de toxina botulínica se ha convertido en la primera opción de tratamiento para esta entidad nosológica, hay una mayor sensibilidad a la toxina, debido al daño relativo del nervio facial.
Objetivo. Describir las características clínicas y del tratamiento con toxina botulínica en un grupo de pacientes.
Métodos. Se realizó un estudio descriptivo, longitudinal, en pacientes con espasmo hemifacial, que fueron tratados con neurotoxina botulínica en el Centro Internacional de Restauración Neurológica, en La Habana, Cuba, en el período comprendido entre los años 2009 y 2018. Se tomó una muestra no probabilística de 50 pacientes.
Resultados. La edad promedio de los pacientes fue de 67,79 ± 13,71 años. Se nota un predominio ligero de los afectados de la hemicara izquierda, n=26 (52 %). Consideramos significativa la reducción del porciento de deterioro funcional de manera general, así como la del valor máximo de la escala de severidad de Jankovic de manera específica. La media de escala de mejoría fue de 2,92 y ± 0,94.
Conclusiones. Se observó un predominio de las edades entre 60 y 79 años. La edad de inicio fue de 51,97 ±15,08 años. La escala de evaluación clínica del espasmo hemifacial de Martí, Tolosa y Alom aplicada a los pacientes demostró la eficacia del tratamiento con toxina botulínica.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Jost, WH, Palmowski-Wolfe, A and Laskawi, R. Therapy of Hemifacial Spasm with BotulinumToxin. s.l. : Fortschr Neurol Psychiatr., 2017. Vol. 85, 4.

  2. Betancourt Nápoles, R;. Guía para el tratamiento con toxina botulínica de las distoníasfocales, el espasmo hemifacial y la espasticidad. s.l. : Rev Cubana Neurol Neurocir, 2014. Vol. 4, 2,pp. 192–200.

  3. Praween, Lolekha, Arthita, Choolam and Kongkiat, Kulkantrakorn. A comparative crossoverstudy on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinumtoxin injection techniques. s.l. : Neurological Sciences, 2017. Vol. 38, 11, pp. 2031–2036.

  4. Jamjoon, AB; Anderson, RL; Jordan, DR; Patrinely JR;. Bilateral hemifacial spasm. s.l. : Journalof Clinical Neuro-ophthalmology, 1990. Vol. 10, pp. 153-154.

  5. Felício, AC; Godeiro-Junior, CDO; Borges, V; Silva, SM; Ferraz, HB;. Bilateral hemifacial spasm:a series of 10 patients with literature review. s.l. : Parkinsonism & Related Disorders, 2008. Vol. 14,2, pp. 154–156.

  6. Carvalho da Silva Martins, Warley , Freitas de Albuquerque, Lucas Alverne and Cardoso deCarvalho, Gervásio Teles . Tenth case of bilateral hemifacial spasm treated by microvasculardecompression: Review of the pathophysiology. s.l. : Surg Neurol Int., 2017. 10.4103/sni.sni_95_17.

  7. Carlo, C; Matteo, B; Simona, L;. A comparative study of primary and secondary hemifacialspasm. s.l. : Archives of Neurology, 2006. Vol. 63, 3, pp. 441–444.

  8. Sindou, MP. Microvascular decompression for primary hemifacial spasm. Importance ofintraoperative neurophysiological monitoring. s.l. : Acta Neurochirurgica, 2005. Vol. 147, 10, pp.1019–1026.

  9. Guan, HX; Zhu, J; Zhong , J;. Correlation between idiopathic hemifacial spasm and the MRIcharacteristics of the vertebral artery. s.l. : Journal of Clinical Neuroscience, 2011. Vol. 18, 4, pp. 528–530.

  10. Hermier M. Imaging of hemifacial spasm. s.l. : Neurochirurgie, 2018.10.1016/j.neuchi.2018.01.005..

  11. Andrew G. and Neil R. Miller. Alleviating Maneuvers for Benign Essential Blepharospasmand Hemifacial Spasm. 2016. Vol. 134, 11, pp. 1253-1254.

  12. Tan, NC; Tan, EK; Khin, LW;. Diagnosis and misdiagnosis of hemifacial spasm: a clinical andvideo study. s.l. : Journal of Clinical Neuroscience, 2004. Vol. 11, 2, pp. 142-144.

  13. Wabbels, B; Roggenka, P;. Botulinum toxin in hemifacial spasm: the challenge to assess theeffect of treatment. s.l. : J Neural Transm, 2012. Vol. 119, pp. 963–980.

  14. Lu, AY; Yeung, JT; Gerrard , JL; Michaelides, EM;. Hemifacial Spasm and NeurovascularCompression. Review Article. s.l. : Scientific World Journal, 2014.

  15. Kenney, C and Jankovic, J. Botulinum toxin in the treatment of blepharospasm andhemifacial spasm. 2008. Vol. 115, pp. 585–591.

  16. Lefaucheur JP. New insights into the pathophysiology of primary hemifacial spasm. s.l. :Neurochirurgie, 2018. 10.1016/j.neuchi.2017.12.004.

  17. Marsh, Wallace A , Monroe, Deirdre M and Brin, Mitchell F . Systematic review and metaanalysisof the duration of clinical effect of onabotulinumtoxinA in cervical dystonia. s.l. : BMCNeurology, 2014. Vol. 14, 91.

  18. Safarpour, Y and Jabbari, B. Botulinum Toxin Treatment of Movement Disorders. s.l. : CurrTreat Options Neurol., 2018. Vol. 24, 20.

  19. Jankovic J. Botulinum toxin: State of the art. s.l. : Mov Disord., 2017. Vol. 32, 8.

  20. Schrader, C, Ebke, M and Adib Saberi , F. Botulinum toxin therapy in patients with oralanticoagulation: is it safe? 2018. Vol. 135, 12, pp. 173-176.

  21. Maragoto, C; Mendoza, F; Alvarez, L; Morales, JM; Rodriguez, G; Alvarez, E;. Clinicalcharacterization of cranio-cervical dystonia treated with botulinum toxin type A. s.l. : MovementDisorders, 2002. Vol. 17, 5.

  22. Maragoto Rizo, C; Vera Cuesta, H; Ortega González, MA; Gómez, L; González, TB;.Uso dela toxina botulínica tipo a en el tratamiento integral de pacientes con Parálisis Cerebral. s.l. : REVNEUROL, 2006. Vol. 42, 6.

  23. Dolly, JO and Aoki, KR. The structure and mode of action of different botulinum toxins.s.l.: Eur J Neurol, 2012. Vol. 13, pp. 1-9.

  24. Dressler, Dirk , Tacik, Pawel and Saberi, Fereshte Adib . Botulinum toxin therapy of cervicaldystonia: comparing onabotulinumtoxin A (Botox) and incobotulinumtoxin A (Xeomin). s.l. : JNeural Transm, 2014. Vol. 121, pp. 29-31. 10.1007/s00702-013-1076-z.

  25. Poulain, B and Humeau, Y. Le mode d’action des neurotoxines botuliques: aspectspathologiques, cellulaires et moléculaires. s.l. : Ann Réadap Med Phys, 2013. Vol. 46, pp. 265- 275.

  26. Erbguth, F. Historical note on the therapeutic use of botulinum toxin in neurologicaldisorders. s.l. : J neurol neurosurg Psychiatry, 1996. Vol. 60, 51.

  27. Carruthers, A. History of the clinical use of botulinum toxin A and B. s.l. : Clin Dermatol,2013. Vol. 21, pp. 469-72.

  28. Kutschenko A, Weisemann J, Kollewe K. Botulinum neurotoxin serotype D - A potentialtreatment alternative for BoNT/A and B non-responding patients. s.l. : Clin Neurophysiol, 2019. Vol.

  29. Baduni, Apala and Krishnamoorthy, Bhuvana. Treatment of hemifacial spasm in patient withhemifacial atrophy using combination therapy (ultrasound therapy and TENS): a case report. s.l. :Korean J Pain, 2017. Vol. 30, pp. 304-307.

  30. Cicik, Erdogan , Yildirim, Rengin and Arici, Ceyhun . Effect of Hemifacial Spasm onIntraocular Pressure Measurement. s.l. : Journal of Ophthalmology, 2018. Vol. 2, p. 4.

  31. Batisti, Jean Pierre Mette, Kleinfelder, Alais Daiane Fadini and Galli, Natália Bassalobre .Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and welltolerated. s.l. : Arq Neuropsiquiatr, 2017. Vol. 75, 2, pp. 87-91.

  32. Li, Y.J. ; Huang, Y. ; Ding, Q. ; Gu, Z.H.; Pan, X.L. Evaluation of concentrations of botulinumtoxin A for the treatment of hemifacial spasm: a randomized double-blind crossover trial. s.l. :Genet. Mol. Res., 2015. Vol. 14, 1, pp. 1136-1144.

  33. Bilyk, Jurij R. , Yen, Michael T. and Bradley,, Elizabeth A. . Chemodenervation for theTreatment of Facial Dystonia. s.l. : Ophthalmic Technology Assessment, 2018. pp. 1-9.

  34. Fernandez HH, Pagan F, Danisi F,. Prospective Study Evaluating Incobotulinumtoxin A forCervical Dystonia or Blepharospasm: Interim Results from the First 145 Subjects with CervicalDystonia. s.l. : Tremor Other Hyperkniet Mov, 2013. Vol. 3.

  35. O’Dell, M.W.; Brashear, A.; Jech, R.; Lejeune, T.; Marque, P.; Bensmail et. al. Dosedependenteffects of abobotulinumtoxina (dysport) on spasticity and active movements in adultswith upper limb spasticity: Secondary analysis of a phase 3 study. s.l. : PMR, 2017.

  36. Frevert, Jürgen , Ahn, Ki Young and Park, Mee Young. Comparison of botulinumneurotoxin type A formulations in Asia. s.l. : Clinical, Cosmetic and Investigational Dermatology,2018. Vol. 11, pp. 327–331.

  37. Dressler, D. Long-term efficacy and safety of incobotulinumtoxin A injections in patientswith cervical dystonia. s.l. : J Neurol Neurosurg Psychiatry, 2013. Vol. 84, pp. 1014-1019.

  38. Rowe, FJ. Toxina botulínica para el tratamiento del estrabismo (Revision Cochranetraducida). s.l. : Wiley & Sons, 2009. Vol. 2.

  39. Jitpimolmard, S and Tiamkao, S. Long term results of botulinum toxin type A (Dysport) inthe treatment of hemifacial spasm: report of 175 cases. s.l. : Journal of Neurology, Neurosurgeryand Psychiatry, 1998. Vol. 64, 6, pp. 751-757.

  40. Bentivoglio , AR; Lalongo, T; Bove, F; De Nigris, F; Fasano, A. Retrospective evaluation of thedose equivalence of Botox and Dysport in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. s.l. : Neurol Sci, 2012. Vol. 33, pp. 261–267.

  41. Barbosa, ER; Takada, LT; Costa, RM; Gonçalves, LR; Chien, EH. Botulinum toxin type A inthe treatment of hemifacial spasm: an 11-year experience. 2010. Vol. 68, 4, pp. 502-505.

  42. Defazio, G; Berardelli, A; Abbruzzese, G; Coviello, V; De Salvia, R; Federico, F; et.al. Primaryhemifacial spasm and arterial hypertension: a multicenter case-control study. s.l. : Neurology, 2000.Vol. 54, 5, pp. 1198-1200.

  43. Cannon, PS; MacKenzie, KR; Cook, AE; Leatherbarrow, B. Difference in response tobotulinum toxin type A treatment between patients with benign essential blepharospasm andhemifacial spasm. s.l. : Clinical and Experimental Ophthalmology, 2010. Vol. 38, pp. 688–691.

  44. Defazio, G; Martino, D; Aniello , MS; Masi, G; Logroscino, G; Manobianca, G; et al. Influenceof age on the association between primary hemifacial spasm and arterial hypertension. s.l. : JNeurol Neurosurg Psychiatry, 2003. Vol. 74, 7, pp. 979-981.

  45. Abbruzzese, G; Berardelli, A; Defazio, G;. Hemifacial spasm. s.l. : Handbook of ClinicalNeurology, 2011. Vol. 100, pp. 675–680.

  46. Setthawatcharawanich, S; Sathirapanya, P; Limapichat, K; Phabphal, K;. Factors associatedwith quality of life in hemifacial spasm and blepharospasm during long-term treatment withbotulinum toxin. s.l. : Qual Life Res, 2011. Vol. 20, pp. 1519–1523.

  47. Oliveira, FC, et al. Influência da toxina botulínica tipo A na função lacrimal de pacientescom distonias faciais. s.l. : Arq. Bras. Oftalmol., 2010. Vol. 73, 5, pp. 405-408.

  48. Thussu, A, Barman, C and Prabhakar, S. Botulinum toxin treatment of hemifacial spasm andblepharospasm : objective response evaluation. s.l. : Neurol India., 1999. Vol. 47, 3, pp. 206-209.

  49. Sorgun, MH. Botulinum toxin injections for the treatment of hemifacial spasm over 16years. s.l. : Clin Neurosci, 2015. 26100157.

  50. Ababneh, Osama H, Cetinkaya, Altug and Kulwin, Dwight R . Long‐term ecacy and safetyof botulinum toxin A injections to treat blepharospasm and hemifacial spasm. s.l. : Clinical andExperimental Ophthalmology, 2013.

  51. Yoshimura, DM; Aminoff, MJ; Tami, TA; Scott, AB;. Treatment of Hemifacial Spasm withbotulinum toxin. s.l. : Muscle Nerve, 1992. Vol. 15, pp. 1045-1049.




2020     |     www.medigraphic.com